Maternal Anti-Dengue IgG Fucosylation Predicts Susceptibility to Dengue Disease in Infants

Highlights

- Maternal anti-dengue afucosylation predicts symptomatic infections in infants
- Afucosylated IgGs enhance dengue infections by promoting FcγRIIIa signaling
- Dengue virus replication required calcineurin signaling network interactions

Authors

Natalie K. Thulin, R. Camille Brewer, Robert Sherwood, ..., Sheng Zhang, Daniel H. Libraty, Taia T. Wang

Correspondence
taiawang@stanford.edu

In Brief

Thulin et al. show that reduced fucosylation (afucosylation) of maternally derived anti-dengue IgGs is associated with symptomatic dengue infections in infants. Afucosylation of dengue immune complexes promotes FcγRIIIa signaling in monocytes, in turn enhancing infection through a post-entry pathway that is dependent on the calcineurin signaling network.
Maternal Anti-Dengue IgG Fucosylation Predicts Susceptibility to Dengue Disease in Infants

Natalie K. Thulin,1 R. Camille Brewer,1 Robert Sherwood,2 Stylianos Bournazos,3 Karlie G. Edwards,1 Nitya S. Ramadoss,4 Jeffery K. Taubenberger,6 Matthew Memoli,5 Andrew J. Gentles,1,6 Prasanna Jagannathan,1,8 Sheng Zhang,2 Daniel H. Libraty,7 and Taia T. Wang1,8,9,10,*

1Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
2Proteomics Facility, Institute of Biotechnology, Cornell University, Ithaca, NY 14853, USA
3The Laboratory of Molecular Genetics and Immunology, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA
4Department of Immunology and Rheumatology, Stanford University, Stanford, CA 94305, USA
5Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
6Department of Biomedical Data Science, Stanford University, Stanford, CA 94305, USA
7University of Massachusetts Medical School, Worcester, MA, USA
8Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA
9Chan Zuckerberg Biohub, San Francisco, CA 94518, USA
10Lead Contact
*Correspondence: taiawang@stanford.edu
https://doi.org/10.1016/j.celrep.2020.107642

SUMMARY

Infant mortality from dengue disease is a devastating global health burden that could be minimized with the ability to identify susceptibility for severe disease prior to infection. Although most primary infant dengue infections are asymptomatic, maternally derived anti-dengue immunoglobulin G (IgGs) present during infection can trigger progression to severe disease through antibody-dependent enhancement mechanisms. Importantly, specific characteristics of maternal IgGs that herald progression to severe infant dengue are unknown. Here, we define >10% afucosylation of maternal anti-dengue IgGs as a risk factor for susceptibility of infants to symptomatic dengue infections. Mechanistic experiments show that afucosylation of anti-dengue IgGs promotes FcγRIIIa signaling during infection, in turn enhancing dengue virus replication in FcγRIIIa+ monocytes. These studies identify a post-translational modification of anti-dengue IgGs that correlates with risk for symptomatic infant dengue infections and define a mechanism by which afucosylated antibodies and FcγRIIIa enhance dengue infections.

INTRODUCTION

Antibody-mediated inflammatory responses are critical in immunity against infectious organisms. These responses can promote pathogen clearance but can also exacerbate symptoms during infections (Bournazos et al., 2017). Antibody-mediated inflammation is triggered when pathogens or infected cells are bound by immunoglobulin G (IgG) antibodies, forming immune complexes that signal through Fc gamma receptors (FcγRs) on effector cells. The outcome of effector cell responses depends on the balance of activating to inhibitory (A/I) FcγR signaling that arises from interactions with Fc domains within immune complexes. Activating FcγRs contain immunoreceptor tyrosine-based activation motifs (ITAMs), while the inhibitory FcγR balances this activity through immunoreceptor tyrosine-based inhibitory motif (ITIM) signaling. One factor that modulates the ratio of A/I FcγR signaling is the glycosylation state of the IgG Fc domains within immune complexes. For example, sialylation of the Fc promotes anti-inflammatory effector responses, whereas absence of core fucosylation, afucosylation, of the Fc is pro-inflammatory due to increasing affinity of the Fc for the activating FcγRIIa, found on natural killer (NK) cells, as well as on subsets of macrophages and monocytes (Anthony et al., 2011; Bournazos et al., 2017; Rafiq et al., 2013). The second major determinant of A/I FcγR signaling by immune complexes is the distribution of IgG subclasses within the complex, with IgG1 being the dominant subclass promoting pro-inflammatory responses and IgG2 signaling through the inhibitory FcγR (Pincetic et al., 2014).

Dengue virus infections are unusual in that non-neutralizing anti-dengue virus IgGs can play a central role in triggering progression to the severe forms of disease through antibody-dependent enhancement (ADE) mechanisms (Anderson et al., 2014; Burke et al., 1988; Chau et al., 2009; Guzmán et al., 1990; Halstead et al., 1970; Katzelnick et al., 2017; Libraty et al., 2009; Sangkawibha et al., 1984; Wang et al., 2017). ADE can occur in the presence of reactive, non-neutralizing IgGs, as are found in secondary heterologous dengue infections or in primary infections in infants of dengue-immune mothers due to acquisition of anti-dengue virus IgGs during gestation (Halstead et al., 1970; Klöks et al., 1988; Simmons et al., 2007). These
antibodies are thought to promote disease by forming immune complexes with the virus that modulate infection in FcγR-bearing cells, primarily monocytes and macrophages, leading to higher viral titers and altered cytokine production during infection (Aye et al., 2014; Durbin et al., 2008; Kou et al., 2008; Thein et al., 1997). Still, the vast majority of dengue infections that occur in the presence of non-neutralizing IgGs are asymptomatic, and specific features of antibodies that enhance one’s basal susceptibility for dengue disease are unknown. Importantly, mortality rates in severe dengue can exceed 20% when patients are not hospitalized, but can be reduced to <1% with in-patient care (Anderson et al., 2014; Gordon et al., 2013). Therefore, the identification of serologic markers for increased baseline susceptibility to dengue disease could dramatically reduce mortality associated with these viruses by enabling early hospitalization of those at highest risk for disease progression.

Because maternal IgGs are transferred to the fetus during gestation, we hypothesized that the repertoire of maternal anti-dengue virus IgG Fc domains might impact basal susceptibility of infants to disease during dengue virus infections. To address this, we performed a global analysis of maternal anti-dengue IgG Fc domain features from a prospective cohort of mothers and infants in a dengue-endemic region of the Philippines in order to define characteristics that predicted progression to significant infant dengue disease. We found that maternal anti-dengue IgGs enriched for afucosylated Fc glycoforms predicted clinically significant disease in their infants during primary dengue infections. Because afucosylation enhances affinity of the Fc for FcγRIIIa, this suggested a role for this receptor in the pathogenesis of dengue disease. We therefore performed studies to dissect the mechanism by which FcγRIIIa and afucosylated IgGs impact dengue virus infections. Our findings identify a pathway by which dengue replication can be enhanced through a FcγRIIIa signaling mechanism requiring the calcineurin signaling network. These studies identify a mechanistic basis for differential susceptibility to dengue disease based on the presence of afucosylated anti-dengue IgGs and suggest novel strategies for the treatment of dengue virus infections.

RESULTS

Maternal Anti-Dengue Fucosylation Predicts Susceptibility to Clinically Significant Disease during Infant Dengue Infections

Maternal IgG levels in the serum of newborns generally match or exceed those in maternal serum (1,012 mg/mL IgG), and the half-life of maternal IgGs in infants is >40 days (Watanaveeradej et al., 2003). Thus, when a mother is seropositive for dengue viruses, maternal anti-dengue IgGs have the potential to modulate infant dengue infections for over 1 year after birth (Alkan Ozdemir et al., 2016; Nicoara et al., 1999; Simmons et al., 2007; Thompson et al., 2016).

To define specific maternal anti-dengue IgG features that herald risk for infant dengue disease, we performed a global analysis of anti-dengue envelope (E) IgGs in mothers of infants with symptomatic (febrile) or asymptomatic primary dengue infections. To do this, we studied samples from a prospective cohort in San Pablo, Laguna, Philippines, a dengue-endemic region. After delivery, infants were followed rigorously for primary dengue infections, including documentation of subclinical infections evidenced by seroconversion (Capeding et al., 2010; Libraty et al., 2009).

Given the role of FcγRs in ADE of dengue virus infections, we first asked whether any maternal anti-E Fc glycosylation patterns could predict susceptibility to infant dengue disease. Characterization of anti-E IgG Fc glycoforms showed that mothers of infants who had clinically significant (symptomatic) primary dengue infections had significantly increased levels of afucosylated anti-E Fc glycoforms compared with mothers of infants who had asymptomatic primary infections (Figure 1A). Indeed, ≥10% afucosylated Fc glycans was predictive of elevated risk for symptomatic infant dengue infections; this threshold predicted symptomatic infections in infants with a positive predictive value of 88%. Specificity of this marker was 93%, indicating that it nearly always predicted symptomatic dengue infections in infants. Sensitivity was lower, 46%, as many, but not all, symptomatic infections could be predicted using this serologic marker. Even omitting the sample with the highest level of afucosylation in the symptomatic group, the 10% threshold remained predictive with unchanged specificity (93%) and slightly reduced sensitivity (43%). Interestingly, this specific threshold of afucosylation was also identified in a prior study of hospitalized dengue patients; this prior study found that anti-E IgG with ≥10% afucosylated Fc glycans was predictive of the most severe disease outcomes during acute dengue infections that occurred in the presence of reactive, non-neutralizing IgGs (Wang et al., 2017). Aside from Fc fucosylation, other Fc glycoforms did not vary between mothers of infants with symptomatic and asymptomatic primary dengue infections (Figure 1B).

Besides Fc glycosylation, the other features that can impact the A/I ratio of Fc-FcγR interactions were also measured. Extensive characterization of the maternal anti-E IgG response showed that symptomatic infant dengue infections could not be predicted by the IgG1/IgG2 ratio of anti-E subclasses, a measurement that accounts for the most abundant IgG subclasses, with IgG1 having increased affinity for activating FcγRs over IgG2 (Figure 1C). The distribution of all maternal anti-E IgG subclasses, the titer of anti-E IgGs, and the binding avidity of anti-E IgGs (Figures 1D–1F) were also not different between groups. In addition, there was no correlation between either symptomatic infant dengue infections or the levels of maternal anti-E afucosylation with infant sex, age at infection, days of fever during symptomatic infections, or serotype of the infecting dengue virus strain (Table S1). Because anti-NS1 IgGs can modulate the severity of dengue infections, we further assessed whether the maternal titer of anti-NS1 IgGs predicted symptomatic dengue infections in their infants and found no correlation (Figure S1A) (Hertz et al., 2017; Jayathilaka et al., 2018). In addition, there was no significant difference in the abundance of anti-NS1 or total IgG Fc fucosylation from mothers of infants with symptomatic or asymptomatic primary dengue infections (Figure S1B). The presence of ≥10% afucosylated glycans on anti-E IgG was the only factor identified in our characterizations that predicted risk for dengue disease in infants. Because Fc afucosylation increases affinity for FcγRIIIa, this finding pointed toward a role for FcγRIIIa in antibody-enhanced dengue infections.
FcγRIIIa Signaling Is Driven by the Fucosylation Level in Dengue Immune Complexes and Enhances Dengue Virus Replication in Human U937 Monocytes

To study how FcγRIIIa signaling by dengue immune complexes might be impacted by variable levels of anti-E fucosylation, we used the maternal IgGs to generate dengue immune complexes and defined their signaling capacity in a FcγRIIIa reporter assay. This showed a linear correlation between endogenously produced levels of anti-E afucosylation and FcγRIIIa-mediated signaling (Figure 2A). Next, we generated dengue virus immune complexes using pooled maternal IgGs with R10% or <10% afucosylation of anti-E IgG; immune complexes with R10% afucosylation drove significantly higher FcγRIIIa signaling (Figure 2B). To assess whether anti-E domain specificity might modulate FcγRIIIa signaling activity, we expressed monoclonal antibodies (mAbs) that bound to distinct domains of the E protein with fucosylated or afucosylated Fc glycans. All mAbs triggered significantly enhanced FcγRIIIa signaling when expressed with afucosylated Fc glycoforms regardless of their anti-E binding specificity (Figure 2C; Figure S2; Table S2).

Although FcγRIIIa is present on macrophage and pro-inflammatory monocyte subsets that are associated with dengue disease, FcγRIIIa is not expressed on human monocytic or other granulocytic lineage cell lines that are often used to study ADE of dengue virus infections, such as THP-1, K562, or U937 cells (Fleit et al., 1982; Tridandapani et al., 2002; van de Winkel and Anderson, 1991). These cell lines express the high-affinity activating FcγR, FcγRI (except for K562 cells), along with the low-affinity FcγRs, activating FcγRIIa and inhibitory FcγRIIb. Further, primary cells and in vivo mouse models are not robust systems for studying the role of FcγRIIIa in dengue infections because FcγRIIIa is unstable on primary monocytes/macrophages that are cultured ex vivo (Ong et al., 2019; Wang lab, unpublished data), and mouse models that are humanized for FcγR expression, and thus express FcγRIIIa, are immunocompetent, rendering them incompatible with current dengue infection models (Smith et al., 2012; Zellweger and Shresta, 2014). Thus, to dissect the role of FcγRIIIa in ADE of dengue infections, we generated human U937 monocytes expressing different combinations of the activating low-affinity FcγRs, FcγRIIIa and...
FcγRIIIa (Figures S3A–S3F). FcγRIIIa was previously shown to have a role in ADE of dengue infections (Boonnak et al., 2013), but a role for FcγRIIIa has not been defined.

First, U937 monocytes expressing different combinations of FcγRIIa and FcγRIIIa were infected with immune complexes made from dengue virus and five different maternal IgGs from the San Pablo cohort. Single-cycle infection was enhanced by up to 300% in monocytes expressing FcγRIIIa (FcγRIIa+FcγRIIIa+) compared with those expressing only FcγRIIa (FcγRIIa+FcγRIIIa−/C0) (Figure 3A). Next, we determined whether FcγRIIIa ITAM signaling was required for FcγRIIIa-mediated ADE, using cells expressing signaling-competent (FcγRIIa+FcγRIIIa+) or signaling-null [FcγRIIa+FcγRIIIaITAM−] versions of FcγRIIIa (Figure S3A) (Bla´ zquez-Moreno et al., 2017). Interestingly, the FcγRIIIa-mediated enhancement of infection required ITAM signaling (Figure 3A). To assess whether anti-E domain specificity might contribute to the involvement of FcγRIIIa in ADE, we tested the panel of afucosylated anti-E mAbs for their ability to modulate dengue infections. In all cases, anti-E mAbs mediated significantly increased infection in FcγRIIa+FcγRIIIa+ cells over U937 monocytes expressing only FcγRIIa. As observed with the maternal IgG, FcγRIIIa-mediated ADE required FcγRIIIa signaling in all cases (Figure 3B). Overall, these studies showed that increasing the cellular A/I FcγR signaling ratio via FcγRIIIa ITAM signaling promoted ADE of dengue virus infections.

We next asked whether modulating cellular A/I FcγR signaling in parallel with dengue infection might impact ADE. Crosslinking individual FcγRs in FcγRIIa+FcγRIIIa+ U937 cells showed that increased signaling by the activating, ITAM-containing FcγRIIa or FcγRIIIa enhanced cell infectibility, whereas signaling through the inhibitory, ITIM-containing FcγRIIb reduced infection (Figure 3C). These results are consistent with increased A/I signaling ratios promoting ADE of dengue infections, whereas reducing the A/I ratio via FcγRIIb signaling diminished ADE. Additive activating/ITAM signaling through crosslinking FcγRIIa and FcγRIIIa together resulted in the greatest enhancement of infection (Figure 3D). These data supported a mechanism whereby infection...
Figure 3. FcγRlla Signaling Enhances Antibody-Dependent Infection of U937 Monocytes

(A) Infection by dengue immune complexes generated with maternal IgGs was significantly enhanced in FcγRlla+ monocytes, and FcγRlla signaling was required for enhancement in all cases. Red line: FcγRlla+FcγRlla+ cells; black line: FcγRlla+FcγRlla+/C0 cells; broken red line, unfilled circles: FcγRlla-FcγRlla+/ITAM/C0 cells.

(B) The role of FcγRlla signaling in ADE was evaluated by comparison of infection in FcγRlla+FcγRlla+ cells (red), FcγRlla-signaling null FcγRlla+/ITAM/C0 cells (white), and FcγRlla-FcγRlla+ (black) or FcγRlla-FcγRlla- (blue) cells. Immune complexes were generated from dengue virus and afucosylated anti-envelope mAbs 235, B7, 2D22, or C10, which have distinct anti-E binding specificities. In all cases, FcγRlla signaling was required for maximal infection.

(C) Signaling induced by crosslinking of FcγRlla or FcγRlla promoted infection of FcγRlla+FcγRlla+ U937 cells, whereas crosslinking the inhibitory FcγRllb, FcγRlla, reduced infectibility of cells.

(D) Combined signaling by activating FcγRlla and FcγRlla during infection resulted in maximal infectibility of FcγRlla+FcγRlla+ U937 cells.

(E) Increasing cellular calcium flux promoted infection of FcγRlla+FcγRlla+ U937 cells.

*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (unpaired Student’s t test). Data are representative of a minimum of three experiments. Error bars represent the standard error of three technical replicates. Replicates were performed at all points; where error bars are not present, the standard error was smaller than the width of the symbol marking the data point.
was enhanced by cellular calcium flux, which is triggered by ITAM signaling (Bolland and Ravetch, 1999; Hippen et al., 1997). To verify this, we treated cells with the calcium ionophore, ionomycin, prior to infection. This treatment increased ADE of infection in a dose-dependent manner (Figure 3E).

Having found that FcγRIIIα ITAM signaling could increase dengue infections, we next sought to determine whether FcγRIIIα might have a separate role in mediating attachment of dengue immune complexes. To investigate this, we used well-characterized blocking mAbs against FcγRI, FcγRIIIa, or FcγRIIa to prevent immune complex attachment to cells prior to infection (Boruchov et al., 2005; Fleit et al., 1982; Mandelboim et al., 1999; Tamm and Schmidt, 1996; Zeller and Sullivan, 1993). In FcγRIIIa+FcγRIIIa+U937 cells, blocking either FcγRI or FcγRIIa during immune complex attachment prevented ~50% infection, whereas blocking FcγRI alone with the blocking mAb, 3G8, did not inhibit infection (Figure 4A) (Boruchov et al., 2005; Fleit et al., 1982; Mandelboim et al., 1999; Tamm and Schmidt, 1996; Zeller and Sullivan, 1993). Combining blocking mAbs for FcγRI and FcγRIIa inhibited infection by ~80%, and inclusion of the FcγRIIIa blocking mAb did not further diminish infection. In freshly isolated primary monocytes, blocking attachment of immune complexes to FcγRIIa prior to entry prevented nearly all infection, whereas blocking FcγRI, FcγRIIb, or FcγRIIIa did not reduce infection (Figure 4B). These results are consistent with studies showing that FcγRIIa on monocytes mediates dengue immune complex attachment and entry (Boonnak et al., 2013; Kou et al., 2008; Littaua et al., 1990) and suggested that the FcγRIIa-mediated enhancement is due to modulation of a post-attachment step of infection.

Inhibitors of the Calcineurin Signaling Network Block Dengue Virus Replication

Engagement and crosslinking of the activating FcγRs trigger phosphorylation of ITAM domains by Src family kinases and intracellular calcium flux (Bournazos and Ravetch, 2015; Hippen et al., 1997). Calcium flux, in turn, activates calcineurin, a serine/threonine phosphatase that recognizes a host of substrates, scaffolds, and regulator proteins through specific docking motifs (Roy and Cyert, 2009; Roy et al., 2007). To dissect how enhanced A/I ratios contribute to ADE of dengue infections, we treated cells with inhibitors of the ITAM signaling pathway prior to infection. First, FcγRIIa*FcγRIIIa* monocytes were treated with PRT, an inhibitor of Syk tyrosine kinase activity, required for initiation of ITAM signaling (Lowell, 2011; Reilly et al., 2011). This inhibited dengue infection (Figure S5A), supporting the requirement for ITAM signaling in ADE of dengue virus infection.

Next, we tested the hypothesis that ADE of dengue infection is enhanced by calcium flux via the calcineurin signaling network. The small-molecule inhibitor INCA-6 (Bretz et al., 2013) and the peptide inhibitor 11R-VIVIT (VIVIT) (Aramburu et al., 1999) act selectively to prevent the association of calcineurin with substrates that bind via the calcineurin PxxIT docking motif (Roy et al., 2007). Both inhibitors prevented dengue virus infection in U937 monocytes (Figures 5B and 5C). Inhibitors were used at concentrations that did not impact cell viability (Figure S4). To assess the specificity of this observation for dengue infections, we studied the impact of the VIVIT inhibitor on infection of U937 cells by influenza A viruses. Although dengue serotypes 2 and 3 were robustly inhibited by VIVIT, influenza A viruses (H1N1 A/Netherlands/602/2019 and H3N2 A/HK/1/1968 strains) were not affected by this inhibitor of the calcineurin signaling network (Figure 5D). We next treated cells with the VIVIT inhibitor during or at different time points after dengue infection to characterize the kinetics of the required calcineurin network activity. Treatment of cells up to 6 h after entry significantly reduced infection, consistent with disruption of a post-entry stage of infection (Figure 5E).

IgG Fucosylation Is Stable over Time, Suggesting Utility as a Predictive Marker for Dengue Disease Risk

To be a useful marker of dengue disease susceptibility, the abundance of Fc afucosylation would have to be stable over time and withstand immune perturbation. To assess stability of this IgG modification, we performed a longitudinal study of IgGs from healthy adults in a North American cohort who were challenged with influenza A virus (Memoli et al., 2015). We characterized IgG afucosylation prior to and over a period of 60 days after influenza infection.
Figure 5. Inhibition of Dengue Infection through Targeted Inhibition of ITAM Signaling Pathway Elements

(A) A small molecule that targets Syk tyrosine kinase (Syk TK), PRT, inhibited dengue infection in FcγRIIa+FcγRIIIa+ U937 monocytes.

(B and C) A small-molecule inhibitor, INCA-6 (B), and a peptide inhibitor, 11R-VIVIT (VIVIT) (C), which act by blocking calcineurin-substrate interactions at the calcineurin PxixIT site, inhibited dengue infections. A scrambled peptide containing the amino acids found in VIVIT (11R VEET) did not inhibit infection (open circles).

(D) Inhibition of dengue viruses (DENV2, DENV3), but not H1N1 or H3N2 influenza viruses (IAVs), was observed using the VIVIT inhibitor (solid lines); scrambled VEET peptide in dashed lines.

(E) Treatment of cells with VIVIT up to 6 h after infection by dengue immune complexes significantly inhibited infection.

(F) Model for susceptibility to clinically significant dengue infections in infants. Infants of mothers who are dengue-immune and have ≥10% afucosylated anti-E IgGs are at elevated risk for symptomatic primary dengue infections due to modulation of FcγRIIa-expressing cells during infection.

(G) Model for the roles of FcγRIIa, FcγRIIIa, and afucosylated dengue immune complexes in ADE. While FcγRIIa supports a majority of viral attachment and entry, FcγRIIIa signaling increases cellular ITAM signaling, ITAM signaling, in turn, triggers calcium flux and modulates the calcineurin signaling network, which supports dengue virus replication.

*p < 0.05, **p < 0.01, ***p < 0.001 [unpaired Student’s t test]. Data are representative of a minimum of three experiments. Error bars represent the standard error of three technical replicates. Replicates were performed at all points; where error bars are not present, the standard error was smaller than the width of the symbol marking the data point.
virus challenge. The abundance of afucosylated glycans was remarkably durable over this period and, despite virus challenge (Figure S6), supporting utility of this serologic marker to guide clinical care of dengue patients.

DISCUSSION

Here, we show that elevated afucosylated Fc glycans (≥10%) on maternal anti-E IgGs is one risk factor for susceptibility of infants to disease during primary dengue virus infections. Mechanistic studies performed to identify how afucosylated anti-E IgGs can impact dengue infections support a model whereby the presence of afucosylated dengue immune complexes triggers a FcγRIIa-modulated infection characterized by increased ITAM signaling. Enhanced ITAM signaling, in turn, promoted dengue infections in U937 monocytes through an intrinsic ADE mechanism (Figure 5F) (Halstead et al., 2010). On a cellular level, the data show a role for FcγRIIa in enhancing ADE of dengue virus infections through cooperativity with FcγRIa. Although FcγRIa acts in virus immune-complex attachment and entry (extrinsic ADE) (Halstead et al., 2010), we show that the increased cellular A/I signaling ratio triggered by afucosylated immune complex-FcγRIIa interactions supports dengue virus infection through calcineurin signaling network interactions requiring the PxxIT docking motif (Figure 5G). This mechanism suggests novel treatment strategies for dengue infections that target this pathway.

An important topic for future studies on the pathogenesis of dengue disease is the cellular activities associated with afucosylated IgGs during dengue infection that were not studied here. We have used percent infection as the readout of activity conferred by anti-dengue Fc afucosylation and of FcγRIIa signaling in ADE of dengue virus infections, yet FcγRIIa signaling activity likely impacts disease pathogenesis through multiple mechanisms, including modulation of cytokine production by FcγRIIa-expressing cells.

Because mortality rates in severe dengue cases can be nearly eliminated with intensive clinical monitoring (Anderson et al., 2014; Gordon et al., 2013), identifying markers for susceptibility to dengue disease could dramatically improve the clinical management of dengue patients. Here we show that maternal IgG Fc fucosylation could be used in the cohort studied to identify a significant subset of susceptible infants. Prospective cohort studies are now needed to examine testing of antibody fucosylation to guide the treatment of primary infant dengue infections and acute dengue infections in non-infant populations.

STAR+METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead Contact
  - Materials Availability
  - Data and Code Availability
  - Key Resources Table

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.celrep.2020.107642.

ACKNOWLEDGMENTS

We thank Martha S. Cyert (Stanford University) for helpful discussions. Support was received from Stanford University, the Chan Zuckerberg Biohub, and the Searle Scholars Program. Research reported in this publication was supported in part by the Bill & Melinda Gates Foundation (grant OPP1188461); the NIH, National Institute of Allergy and Infectious Diseases (NIAID: grant U19AI111825, U01AI144616, R01AI137276, and R01AI139119); and by the Rockefeller University Center for Clinical and Translational Science (grant UL1 TR001866). The influenza A virus challenge study was supported by the Intramural Research Program of the NIAID. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

AUTHOR CONTRIBUTIONS

T.T.W., D.H.L., N.K.T., and R.C.B. designed experiments. T.T.W., N.K.T., R.C.B., R.S., S.Z., S.B., K.G.E., N.S.R., J.K.T., M.M., A.J.G., and P.J. collected and/or analyzed and/or interpreted data. T.T.W. and N.K.T. wrote the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

REFERENCES

Alkan Ozdemir, S., Ozer, E.A., Kose, S., Ilhan, O., Ozturk, C., and Sutcuoglu, S. (2016). Reference values of serum IgG and IgM levels in preterm and term newborns. J. Matern. Fetal Neonatal Med. 29, 972–976.

Anderson, K.B., Gibbons, R.V., Cummings, D.A., Nisalak, A., Green, S., Liamtrakul, D.H., Jarman, R.G., Srikiatkhachom, A., Mammen, M.P., Darunee, B., et al. (2014). A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J. Infect. Dis. 209, 360–368.

Anthony, R.M., Kobayashi, T., Wermeling, F., and Ravetch, J.V. (2011). Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475, 110–113.

Aramburu, J., Yaffe, M.B., López-Rodríguez, C., Cantley, L.C., Hogan, P.G., and Rao, A. (1999). Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 285, 2129–2133.

Aye, K.S., Chandra, K., Win, N., Wai, K.Z., Moe, K., Pinyadee, N., Thiemmea, S., Suttithepumrong, A., Sukpanichnant, S., Prida, M., and Halstead, S.B. (2014). Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar. Hum. Pathol. 45, 1221–1233.

Blázquez-Moreno, A., Park, S., Im, W., Call, M.J., Call, M.E., and Reyburn, H.T. (2017). Transmembrane features governing Fc receptor CD16A assembly with CD16A signaling adaptor molecules. Proc. Natl. Acad. Sci. USA 114, E5645–E5654.

Bolland, S., and Ravetch, J.V. (1999). Inhibitory pathways triggered by ITIM-containing receptors. Adv. Immunol. 72, 149–177.
Boonnak, K., Slike, B.M., Donofrio, G.C., and Marovich, M.A. (2013). Human FcγRIIa cytoplasmic domains differentially influence antibody-mediated dengue virus infection. J. Immunol. 190, 5659–5665.

Boruchov, A.M., Heller, G., Veri, M.C., Bonvini, E., Ravetch, J.V., and Young, J.W. (2005). Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 115, 2914–2923.

Bournazos, S., and Ravetch, J.V. (2015). Fc receptor pathways during active and passive immunization. Immunol. Rev. 268, 88–103.

Bournazos, S., Wang, T.T., Dahan, R., Maamary, J., and Ravetch, J.V. (2017). Signaling by Antibodies: Recent Progress. Annu. Rev. Immunol. 35, 285–311.

Bretz, C.A., Savage, S., Capozzi, M., and Penn, J.S. (2013). The role of the FcRIII cytoplasmic domains differentially influence antibody-mediated dengue virus infection. J. Immunol. 190, 2015–2028.

Burke, D.S., Nisalak, A., Johnson, D.E., and Scott, R.M. (1988). A prospective study of dengue infections in Bangkok. Am. J. Trop. Med. Hyg. 37, 172–180.

Capedinger, R.Z., Brion, J.D., Caponpon, M.M., Gibbons, R.V., Jerman, R.G., Yoon, L.K., and Libraty, D.H. (2010). The incidence, characteristics, and presentation of dengue infections during infancy. Am. J. Trop. Med. Hyg. 82, 330–336.

Chau, T.N., Hieu, N.T., Anders, K.L., Wolbers, M., Lien le, B., Hieu, L.T., Hien, T.T., Hung, N.T., Farrar, J., Whitehead, S., and Simons, C.P. (2009). Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. J. Infect. Dis. 200, 1893–1900.

de Alwis, R., Smith, S.A., Olivariez, N.P., Messer, W.B., Huyhn, J.P., Wahala, W.M., White, L.J., Diamond, M.S., Baric, R.S., Crowe, J.E., Jr., and de Silva, A.M. (2012). Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl. Acad. Sci. USA 109, 7439–7444.

Dejnirattisai, W., Wongwiwat, W., Supasa, S., Zhang, X., Dai, X., Rouvinski, A., Jummaison, D., Edwards, C., Quyen, N.T.H., Duangchinda, T., et al. (2015). A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol. 16, 170–177.

Durbin, A.P., Vargas, M.J., Wanioneck, K., Hammond, S.N., Gordon, A., Rocha, C., Balmaseda, A., and Harris, E. (2008). Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology 376, 429–435.

Fibriansah, G., Ibarra, K.D., Ng, T.-S., Smith, S.A., Tan, J.L., Ooi, E.K., de Alwis, R., Smith, S.A., Olivarez, N.P., Messer, W.B., Huynh, J.P., Wahala, W.M., White, L.J., Diamond, M.S., Baric, R.S., Crowe, J.E., Jr., and de Silva, A.M. (2012). Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl. Acad. Sci. USA 109, 7439–7444.

Jin, X. (2008). Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J. Med. Virol. 80, 134–146.

Katzelnick, L.C., Gresh, L., Halloran, M.E., Mercado, J.C., Kuan, G., Gordon, A., Balmaseda, A., and Harris, E. (2017). Antibody-dependent enhancement of severe dengue disease in humans. Science 358, 929–932.

Kikis, S.C., Nimmanithi, S., Nisalak, A., and Burke, D.S. (1988). Evidence that maternal dengue antibodies are important in the development of dengue hemorraghic fever in infants. Am. J. Trop. Med. Hyg. 37, 411–419.

Kou, Z., Quin, M., Chen, H., Rodrigo, W.W., Rose, R.C., Schliesinger, J.J., and Jinn, X. (2008). Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J. Med. Virol. 80, 134–146.

Lanciotti, R.S., Calisher, C.H., Gubler, D.J., Chang, G.J., and Vorndam, A.V. (1992). Rapid detection and typing of dengue viruses from clinical samples by using reverse transcription-polymerase chain reaction. J. Clin. Microbiol. 30, 545–551.

Libraty, D.H., Acosta, L.P., Tallo, V., Segubre-Mercado, E., Bautista, A., Potts, J.A., Jerman, R.G., Yoon, I.K., Gibbons, R.V., Brion, J.D., and Capedinger, R. (2009). A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med. 6, e1000171.

Littaua, R., Kurane, I., and Ennis, F.A. (1990). Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J. Immunol. 144, 3183–3186.

Lowell, C.A. (2011). Src-family and Syk kinases in activating and inhibitory pathways in innate immune cells: signaling cross talk. Cold Spring Harb. Perspect. Biol. 3, a002352.

Manelboim, O., Malik, P., Davis, D.M., Jo, C.H., Boyson, J.E., and Strowig, J.T. (1999). Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc. Natl. Acad. Sci. USA 96, 5640–5644.

Memoli, M.J., Czajkowski, L., Reed, S., Athota, R., Bristol, T., Proudfoot, K., Fargis, S., Stein, M., Dunfee, R.L., Shaw, P.A., et al. (2015). Validation of the wild-type influenza A human challenge model H1N1 pdM09: an H(A1N1) pdm09 dose-finding investigational new drug study. Clin. Infect. Dis. 60, 693–702.

Nicoara, C., Zäch, K., Trachsel, D., Germann, D., and Matter, L. (1999). Decay of passively acquired maternal antibodies against measles, mumps, and rubella viruses. Clin. Diagn. Lab. Immunol. 6, 868–871.

Ong, S.M., Teng, K., Newell, E., Chen, H., Chen, J., Loy, T., Yeo, T.W., Fink, K., and Wong, S.C. (2019). A Novel, Five-Marker Alternative to CD16-CD14 Gating to Identify the Three Human Monocyte Subsets. Front. Immunol. 10, 929.

Petricic, A., Bournazos, S., DiLillo, D.J., Maamary, J., Wang, T.T., Dahan, R., Fiebig, B.M., and Ravetch, J.V. (2014). Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 15, 707–716.

Rafiq, S., Butcher, J.P., Cheney, C., Mo, X., Trotta, R., Calignuri, M., Jarjura, D., Trindadapani, S., Muthusamy, N., and Byrd, J.C. (2013). Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J. Immunol. 190, 2702–2711.
Reilly, M.P., Sinha, U., André, P., Taylor, S.M., Pak, Y., Deguzman, F.R., Nanda, N., Pandey, A., Stolla, M., Bergmeier, W., and McKenzie, S.E. (2011). PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopathy and thrombosis in a transgenic mouse model. Blood 117, 2241–2246.

Rillaaran, C.D., Antonopoulos, A., Lefort, C.T., Sonon, R., Azadi, P., Ley, K., Dell, A., Haslam, S.M., and Paulson, J.C. (2012). Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. Nat. Chem. Biol. 8, 661–668.

Rouvinski, A., Guardado-Calvo, P., Barba-Spaeth, G., Duquerroy, S., Vaney, M.C., Kikut, C.M., Navarro Sanchez, M.E., Dejnirattisai, W., Wongwiwat, W., Haouz, A., et al. (2015). Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520, 109–113.

Roy, J., and Cyert, M.S. (2009). Cracking the phosphatase code: docking interactions determine substrate specificity. Sci. Signal. 2, re6.

Roy, J., Li, H., Hogan, P.G., and Cyert, M.S. (2007). A conserved docking site modulates substrate affinity for calcineurin, signaling output, and in vivo function. Mol. Cell 25, 889–901.

Sangkawibha, N., Rojanasuphot, S., Ahandrik, S., Viriyapongse, S., Jatana-sen, S., Salitui, V., Phanthumachinda, B., and Halstead, S.B. (1984). Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am. J. Epidemiol. 120, 653–669.

Sasaki, T., Setthapramote, C., Kurosu, T., Nishimura, M., Asai, A., Omokoko, M.D., Pipattanaboon, C., Pitaksaikul, P., Limkittikul, K., Subcharoen, A., et al. (2013). Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection. Antiviral Res. 98, 423–431.

Simmons, C.P., Chau, T.N., Thuy, T.T., Tuan, N.M., Hoang, D.M., Thien, N.T., Lien le, B., Guye, N.T., Hieu, N.T., Hien, T.T., et al. (2007). Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J. Infect. Dis. 196, 416–424.

Smith, P., DiLillo, D.J., Bournazos, S., Li, F., and Ravetch, J.V. (2012). Mouse model recapitulating human Fcy receptor structural and functional diversity. Proc. Natl. Acad. Sci. USA 109, 6181–6186.

Swanstrom, J.A., Plante, J.A., Plante, K.S., Young, E.F., McGowan, E., Galli-chotte, E.N., Widman, D.G., Heise, M.T., de Silva, A.M., and Baric, R.S. (2016). Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus. MBio 7, e01123-16.

Tamm, A., and Schmidt, R.E. (1996). The binding epitopes of human CD16 (Fc gamma RII) monocalonal antibodies. Implications for ligand binding. J. Immunol. 157, 1576–1581.

Thein, S., Aung, M.M., Shwe, T.N., Aye, M., Zaw, A., Aye, K., Aye, K.M., and Aaskov, J. (1997). Risk factors in dengue shock syndrome. Am. J. Trop. Med. Hyg. 56, 566–572.

Thompson, C.N., Le, T.P., Anders, K.L., Nguyen, T.H., Lu, L.V., Nguyen, V.V., Vu, T.D., Nguyen, N.M., Tran, T.H., Ha, T.T., et al. (2016). The transfer and decay of maternal antibody against Shigella sonnei in a longitudinal cohort of Vietnamese infants. Vaccine 34, 783–790.

Trindade, S., Siefker, K., Teillaud, J.L., Carter, J.E., Wewers, M.D., and Anderson, C.L. (2002). Regulated expression and inhibitory function of Fcgamma RIIb in human monocytic cells. J. Biol. Chem. 277, 5082–5089.

van de Winkel, J.G., and Anderson, C.L. (1991). Biology of human immunoglobulin G Fc receptors. J. Leukoc. Biol. 49, 511–524.

Wang, T.T., Maamary, J., Tan, G.S., Bournazos, S., Davis, C.W., Krammer, F., Schiesinger, S.J., Palese, P., Ahmed, R., and Ravetch, J.V. (2015). Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficiency. Cell 162, 160–169.

Wang, T.T., Sewatanon, J., Memoli, M.J., Wrammert, J., Bournazos, S., Bhu-mik, S.K., Pinsky, B.A., Chokephaibulkit, K., Orlamo, N., Pattanapanyasat, K., et al. (2017). IgG antibodies to dengue enhanced for FcyRIIIa binding determine disease severity. Science 355, 395–398.

Watanaveeradej, V., Endy, T.P., Samakoses, R., Kerdpanich, A., Simasathien, S., Polprasert, N., Aree, C., Vaughn, D.W., Ho, C., and Nisalak, A. (2003). Transplacently transferred maternal-infant antibodies to dengue virus. Am. J. Trop. Med. Hyg. 69, 123–128.

Yang, L., Yang, J.L., Byrne, S., Pan, J., and Church, G.M. (2014). CRISPR/ Cas9-Directed Genome Editing of Cultured Cells. Curr. Protoc. Mol. Biol. 107, 31.1.1–31.1.17.

Zeller, J.M., and Sullivan, B.L. (1993). Monoclonal antibody to the type II Fc receptor for human IgG blocks potentiation of monocyte and neutrophil IgG-induced respiratory burst activation by aggregated C-reactive protein. Cell. Immunol. 149, 144–154.

Zeilweger, R.M., and Shresta, S. (2014). Mouse models to study dengue virus immunology and pathogenesis. Front. Immunol. 5, 151.
**STAR METHODS**

**KEY RESOURCES TABLE**

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| FITC conjugated anti-human FcγRIIa, clone IV.3 | STEMCELL Technologies | Cat#60012FI; RRID: AB_2722545 |
| Brilliant Violet 711 conjugated anti-human FcγRIIa, clone 3G8 | Biolegend | Cat#302044; RRID: AB_2563802 |
| Anti-human FcγRIIb, clone 2B6 | J. Ravetch, Rockefeller University | N/A |
| APC anti-human FcγRI, clone 10.1 | Biolegend | Cat#305014; RRID: AB_1595428 |
| Influenza A NP Monoclonal Antibody (D67J), FITC | Invitrogen | Cat#MA17322; RRID: AB_1017747 |
| anti-E antibody, clone D1-4G2-4-15 | ATCC | Cat#VR-1852; RRID: AB_827205 |
| Fucosylated and afucosylated human monoclonal antibody 23-5G2D2747(4) | (Sasaki et al., 2013) | N/A |
| Fucosylated and afucosylated human monoclonal antibody B7 | (Rouviniski et al., 2015) | N/A |
| Fucosylated and afucosylated human monoclonal antibody 2D22 | (de Alwis et al., 2012) | N/A |
| Fucosylated and afucosylated human monoclonal antibody 753(3) C10 | (Rouviniski et al., 2015) | N/A |
| Fucosylated and afucosylated human monoclonal antibody 5J7 | (de Alwis et al., 2012) | N/A |
| anti-FcγRIIa, clone 3G8 | Biolegend | Cat#302057; RRID: AB_2572005 |
| anti-FcγRIIa clone IV.3 | Stem Cell Technology | Cat#60012; RRID: AB_2722545 |
| **Bacterial and Virus Strains** |        |            |
| DENV2 New Guinea C | BEI Resources | NR-84 |
| A/Hong Kong/1/1968, H3N2 | BEI Resources | NR-28620 |
| A/Netherlands/602/2009, H1N1 | Wang Lab Stock | N/A |
| DENV3 C0360/94 | BEI Resources | NR-48800 |
| **Biological Samples** |        |            |
| Sera collected at birth from 29 dengue seropositive mothers of infants who had primary dengue infections | (Libraty et al., 2009) | ClinicalTrials.gov: NCT00377754 |
| Sera from 8 individuals challenged with Ca/04/2009/H1N1 Vero Grown Virus. Sera were collected prior to challenge as well as on day 30 and 60 post-challenge. | (Memoli et al., 2015) | ClinicalTrials.gov: NCT01646138 |
| **Chemicals, Peptides, and Recombinant Proteins** |        |            |
| Dengue Envelope Protein Serotype 1 | Prospec | DEN-021 |
| Dengue Envelope Protein Serotype 2 | Prospec | DEN-022 |
| Dengue Envelope Protein Serotype 3 | Prospec | DEN-023 |
| Dengue Envelope Protein Serotype 4 | Prospec | DEN-024 |
| 11R-VEET | Thermo Fisher | Cat#CM102281.2 |
| 11R-VIVIT | Thermo Fisher | Cat#CM102281.1 |
| INCA-6 | Abcam | Cat#ab145864 |
| PRT062607 | Fisher Scientific | Cat#NC0664362 |
| Ionomycin | Invivogen | Cat#inh-ion |
| 2F-Peracetyl-Fucose | EMD Millipore | Cat#344827 |
| **Critical Commercial Assays** |        |            |
| Protein G Sepharose 4 Fast Flow resin | GE Healthcare | Cat#17061802 |
| NHS agarose resin | ThermoFisher | Cat#26196 |
| Experimental Models: Cell Lines |        |            |
| FcγRlla“FcγRllla” U937 Cells | This paper | N/A |
| FcγRlla“FcγRllla” U937 Cells | This paper | N/A |

(Continued on next page)
RESOURCE AVAILABILITY

Lead Contact
The lead contact for this study is Taia T. Wang (taiawang@stanford.edu).

Materials Availability
This study did not generate new unique reagents. Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact.

Data and Code Availability
This study did not generate any unique datasets or code. An unpaired Student’s t test was utilized to calculate p value: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Key Resources Table
See attached file

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Clinical cohorts and samples: Samples from mothers of infants who had primary dengue infections were from a study that was approved by the institutional review boards of the Research Institute for Tropical Medicine, Philippines, and the University of Massachusetts Medical School. Mothers and their healthy infants were recruited and enrolled after providing written informed consent (ClinicalTrials.gov NCT00377754) (Libraty et al., 2009). Symptomatic dengue was defined as febrile illness with a positive result by dengue serotype-specific reverse-transcription PCR in acute phase sera (Lanciotti et al., 1992). Clinically inapparent dengue infection (asymptomatic infection) was determined using a hemagglutination inhibition assay (HAI assay); a ≥ four-fold increase in HAI against one or more dengue serotypes in the absence of febrile illness confirmed asymptomatic infection (Libraty et al., 2009). The outcome assessed was clinical phenotype during dengue virus infection (symptomatic infection versus asymptomatic infection) (Table S1). Samples from the controlled influenza A virus challenge study have been previously described (Memoli et al., 2015). The study (ClinicalTrials.gov NCT01646138) was approved by the National Institute of Allergy and Infectious Diseases institutional review board and underwent an ethics review by the NIH Department of Bioethics prior to being conducted. The study was conducted in accordance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines.

METHOD DETAILS

IgG Fc glycan and IgG subclass analysis: Methods for relative quantification of Fc Glycans and IgG subclasses have been previously described (Wang et al., 2015; Wang et al., 2017). Briefly, IgGs were isolated from serum by protein G purification. Antigen-specific IgGs were isolated on NHS agarose resin (ThermoFisher; 26196) coupled to the protein of interest. Mixed envelope proteins from the four DENV serotypes were used (ProSpec; DEN-021, DEN-022, DEN-023, DEN-024). Following tryptic digestion of purified IgG bound to antigen-coated beads, nanoLC-MS/MS analysis for characterization of glycosylation sites was performed on an Ultimate3000 nanoLC (Dionex) coupled with a hybrid triple quadrupole linear ion trap mass spectrometer, the 4000 Q Trap (SCIEX).
MS data acquisition was performed using Analyst 1.6.1 software (SCIEX) for precursor ion scan triggered information dependent acquisition (IDA) analysis for initial discovery-based identification.

For quantitative analysis of the glycoforms at the N297 site across the three IgG subclasses (IgG1, IgG2 and IgG3/G4), multiple-reaction monitoring (MRM) analysis for selected target glycopeptides, was applied using the nanoLC-4000 Q Trap platform to the samples which had been digested with trypsin. The m/z of 4-charged ions for all different glycoforms as Q1 and the fragment ion at m/z 366.1 as Q3 for each of transition pairs were used for MRM assays. A native IgGs trypptic peptide (131-GTLVTVSSAKT-142) with transition pair of, 575.9+2/780.4 was used as a reference peptide for normalization. IgG subclass distribution was quantitatively determined by nanoLC-MRM analysis of trypptic peptides following removal of glycans from purified IgGs with PNGase F. Here the m/z value of fragment ions for monitoring transition pairs was always larger than that of their precursor ions to enhance the selectivity for unmodified targeted peptides and the reference peptide. All raw MRM data were processed using MultiQuant 2.1.1 (SCIEX). All MRM peak areas were automatically integrated and inspected manually. In the case where the automatic peak integration by MultiQuant failed, manual integration was performed using the MultiQuant software.

U937 cell lines: Wild-type U937 cells are FcγRlla-FcγRlla; FcγRlla was deleted from the wild-type line using CRISPR/Cas9 methods to generate FcγRlla FcγRlla monocytes. Wild-type cells were stably transfected for expression of FcγRlla generating the FcγRlla-FcγRlla. A final cell line, FcγRlla-FcγRlla (ITAM−/−), expresses FcγRlla and a variant of FcγRlla that does not associate with the Fc receptor gamma chain, and thus lacks ITAM signaling (Blázquez-Moreno et al., 2017).

The gRNAs to target FcγRlla were designed utilizing DESKGEN software, and inserted into sequence containing U6 promoter and gRNA scaffold (Yang et al., 2014). The gRNA sequence to target human FcγRlla was 5′-GATGTGATGTCGAGAAACCTG3′. The final fragment (Integrated DNA Technologies) was cloned into the pCR-BluntI-Topo vector. Human codon optimized cas9 DNA was obtained from (Addgene, Plasmid #41815). To generate the knockout cell line, U937 cells were transfected with 1.5μg of cas9 and 0.5μg of gRNA via electroporation. The U937 cells were electroporated using Lonza Nucleofector 2b (program W-001) and the Nucleofection Kit C (Lonza, VPA-1004). After electroporation, U937 cells were incubated at 37°C for 48 hours. Following incubation, cells were synchronized at the early S phase using a double thymidine block. The cells were stained with IV.3-FITC, and FcγRlla negative cells were bulk sorted on SH800 sorter. After one bulk sort, the cells were single cell sorted based on negative FcγRlla expression. To generate FcγRlla+, the wild-type cells were nucleasefected with pLJM1-EGFP plasmid (Addgene, Plasmid #19319) that has EGFP replaced with FcγRlla or FcγRlla (ITAM−/−), while the FcγRlla+ cells were nucleasefected with pLJM1- FcγRlla only. Stably transfected clones were selected using 1ug/mL puromycin.

FcγRlla signaling assay: U937 cells were infected with DENV2 New Guinea C (BEI Resources; NR-84) at MOI of 0.2ug/ml 235WT. 48h post infection, cells were washed once with PBS. Infected U937 cells were added to anti-dengue mAbs or purified maternal IgGs. Infected U937 cell immune complexes were washed and added to 100ul of Jurkat-Lucia NFAT CD16 (Invivogen; jktl-nfat-cd16) cell suspension at a concentration 1x10^6cells/ml in IMID media and incubated at 37°C for 24h. 20ul of assay supernatant was then transferred to a 96-well white polystyrene flat bottom plate. 50ul Lucina detection medium QUANTI-Luc (Invivogen; rep-qlc1) was added and luciferase activity was measured using Tecan Infinite M100 with a 0.1 s reading time.

FACS staining of U937 cell lines: U937 cell lines were stained with a fixable live/dead stain (ThermoFisher; L10119). To assess FcγR expression cell lines were stained at 1:100 with a FITC conjugated anti-human FcγRlla antibody, clone IV.3 (STEMCELL Technologies; 60012F); Brilliant Violet 711 conjugated anti-human FcγRII, clone 3G8 (Biolegend; 302044); an FcγRlla antibody clone 2B6 (gifted by the Ravetch lab, Rockefeller University) conjugated to Alexa Fluor 647 (ThermoFisher; A20186) and an APC conjugated anti-human FcγRI, clone 10.1 (Biolegend, 305014) for 30 minutes at 4°C.

Cross-linking of FcγRs for receptor signaling detection: U937 cell lines were treated with mouse anti-FcγRlla/b, clone 3G8 (Biolegend; 302057) at 10ug/ml in Optimem on ice for 30 min. Anti-mouse Fc was then added at 1.25μg per 1 million cells and incubated at 37°C for 3 min to crosslink mAb 3G8. Cells were then lysed in a one to one ratio of cell lysate buffer containing 100mM TRIS-HCL/300mM NaCl/2% Triton X-100 and a protease/phosphatase inhibitor cocktail (ThermoFisher; 88668). Protein concentrations were quantified using BCA Protein Assay Kit (ThermoFisher; 23227) and lysates were treated by boiling for 5 min with Laemmli SDS sample buffer containing 5% β-mercaptoethanol. Cell lysates were run on Mini-PROTEAN® TGX Precast Protein Gels (Bio Rad; 4569930). Blots were blocked 5% BSA in TBS buffer 20mM Tris-HCL/150mM NaCl pH 7.6 for 2 hours and were subsequently incubated with anti-phosphotyrosine secondary antibody (Biolegend; 309302) at 1:1,000 in 5% BSA in TBS, 0.2% Tween-20 (TBST) overnight at 4°C. Blots were washed and incubated with anti-mouse IgG Fc-HRP (Southern Biotech; 1030-05) at 1:10,000 for 1 hour at room temperature. Blots were developed with Western Lightning ECL Pro (Perkin Elmer; NEL120001EA) according to manufacturer’s instructions. The membrane was washed using the Amersham Imager 600 (GE Life Sciences) with auto exposure under chemiluminescent detection settings. Post-imaging, the membrane was washed extensively with TBST before treating with Restore™ Western Blot Stripping Buffer (ThermoFisher; 21059) for 15 min at room temperature. To analyze protein loading, the membrane was re-blocked with 5% BSA in TBST for 2 hour at room temperature before probing with a 1:200 dilution anti-vinculin 7FSF (Santa Cruz Biotechnology; sc-73614) in 5% BSA/TBST for 1 hour at room temperature followed by anti-mouse IgG HRP secondary, as above. The membrane was then treated with chemiluminescent substrate and imaged as described above.

Cross-linking of FcγRs in parallel with infection: Non-TC treated round bottom plates were coated with FcγR specific antibodies in PBS for 1h at 37°C. Coating antibodies: anti-FcγRlla clone IV.3 (Stem Cell Technology; 60012) (at 5ug/ml individually or 2.5ug/ml in conjunction with other antibodies), anti-FcγRIIb clone 2B6 (generously provided by J. Ravetch, Rockefeller University) (at 5ug/ml individually or 2.5ug/ml in conjunction with other antibodies); and anti- FcγRlla, clone 3G8 (Biolegend; 302057)
(at 10µg/ml individually or 5µg/ml in conjunction with other antibodies). Plates were coated at 10µg/ml in PBS of human IgG2/kappa (Sigma Aldrich; AG504) to control for protein coat. Plates were washed twice and 50,000 FcγRlla+ FcγRlla+ U937 cells/well diluted in OPTI-MEM were added to plate and incubated at 4°C for 30min. Immune complexes composed of DENV2 New Guinea C (BEI Resources; NR-84) and 0.2µg/ml mAb 235 were then added to plate and incubated at 37°C for 2h. Cells were washed twice in PBS and re-suspended in OPTI-MEM followed by an incubation for 22 h at 37°C. Percent infection was detected by FACs.

Monoclonal antibody production: Antibodies: 23-SQ2Z7474 (Sasaki et al., 2013), B7 (Dejnirattisai et al., 2015; Rouvinski et al., 2015; Swanstrom et al., 2016), 2D22 (de Alwis et al., 2012; Fibriansah et al., 2015a; Swanstrom et al., 2016), and 753(C10) (Rouvinski et al., 2015; Swanstrom et al., 2016), 752-2 C8 (de Alwis et al., 2012; Rouvinski et al., 2015; Swanstrom et al., 2016), and 5J7 (de Alwis et al., 2012; Fibriansah et al., 2015b; Swanstrom et al., 2016) were expressed in Expi293 cells as follows. For afucosylated variants, Expi293 cells (ThermoFisher; A14527) were split to 2.0 x 10⁶ cells/mL in a 10 mL volume 24h prior to transfection and treated with 100 µM of a fucosyl transferase inhibitor, 2F-Peracetyl-Fucose (Rillahan et al., 2012) (EMD Millipore, 344827). On the day of transfection, 5 µg filter-sterilized DNA (2.5 µg each of heavy and light chain-encoding plasmids) was added to 1mL of Expi293 medium (ThermoFisher Scientific; A1435101) in a fresh tube, and mixed. To this, 13 µL (1.3 µL/mL of total transfection volume) of FectPro transfection Reagent (Polyplus transfection; 116-001) was added. The DNA-transfection reagent mixture was incubated at room temperature for 10 minutes before adding dropwise to 2 mL of the Expi293 cells. The cells were then additionally treated with a final concentration of 4g/L glucose and 3 mM malic acid. The cells were then grown under shaking conditions (125 rpm) at 37°C for 3 days before receiving an additional 4g/L final concentration of glucose. The cells were harvested on day 6 post-transfection, the cell pellet discarded, and the supernatant media filtered before purification. MABS were purified over Protein G Sepharose 4 Fast Flow resin (GE Healthcare; 17061802). The antibodies were buffer exchanged into PBS pH 7.4 prior to use in any cell-based assays.

Cell-based ELISA: Wells of a 96 well plate were seeded with 3x10⁴ vero cells (ATCC; CCL-81). The next day cells were infected with DEN2 New Guinea C (BEI Resources; NR-84) or DEN3 C0360/94 (BEI Resources; NR-48800) MOI 1 for 1 hour, washed, and incubated for 48 h in MEM, 1% methylcellulose, 2% inactivated FBS, antibiotics, and L-glutamine. Cells were fixed with 4% formaldehyde for 30 minutes and permeabilized in 2% inactivated FBS/0.1% saponin/PBS. For analysis of clinical samples, serially diluted maternal sera were incubated for 2 hours at room temperature on cells infected with the virus serotype of the paired infant’s dengue virus infection. For mAb binding assays, mAbs were titrated and incubated for 2 hours at room temperature on DENV2 infected cells. Cells were washed with PBS–0.1% Tween 20 and incubated with mouse anti-human IgG Fc-HRP (Southern Biotech; 9040-05) for 1 hour. Following incubation, the wells were washed and TMB Liquid Substrate (Sigma; T0440) was added and stopped with 1M HCL after approximately 5 minutes. Absorbance at 450 nm was measured; ELISA performed in triplicate.

Antibody-dependent infections: Anti-E mAbs were incubated with dengue viruses for 30 minutes at 37°C to form immune complexes. Afucosylated anti-E mAbs were used where indicated in the text. 5x10⁴ U937 cells were added to the immune complexes (MOI: 4) in RPMI containing 2% heat-inactivated FBS, antibiotics, MEM nonessential amino acid solution, 2-mercaptoethanol, HEPES. Cells were infected for 2 hours at 37°C. Infected cells were stained with a fixable viable/dead stain (ThermoFisher; L34955) for 30 min, fixed with 4% formaldehyde and permeabilized in 2% inactivated FBS, 0.1% saponin in PBS. Cells were stained using an anti-E antibody, clone 4G2 (ATCC; VR-1852) conjugated to Alexa Fluor 647 (ThermoFisher; A20186) at 1:400 for 30 min. The frequency of infected cells was determined by FACs using flow cytometry, defined as the percentage of live, single cells that were positive for mAb 4G2 staining. For infections involving inhibitors or activators of ITAM signaling, U937s were treated with titrated inhibitors: Ionomycin (InvivoGen; inh-ioni), PRT062607 (Fisher Scientific; NC0664362), INCA-6 (Abcam; ab145864), 11R-VIVIT (Thermo Fisher; CM102281.1), or 11R-VEET (Thermo Fisher; CM102281.2) in complete RPMI media for 1h-6h at 37°C prior to infection. Treated cells were washed 2x with PBS before being added to virus.
Avidity ELISA: The avidity ELISA has been described before (Wang et al., 2015). Briefly, Wells of microtiter plates were coated with DENV2 (ProSpec; DEN-022) or DENV3 (ProSpec; DEN-023) E proteins (2.5 μg ml⁻¹ in PBS) for 2 hours at 37°C. Plates were blocked for 30 min with 1% BSA/1% PBS and then incubated with titrated Gentle Ag/Ab Elution Buffer, pH 6.6 (ThermoFisher; 21027) and maternal IgG, which was normalized for optical density of binding to dengue-infected cells and matched for virus serotype of the paired infant’s dengue virus infection. Plates were washed with PBS/0.1% Tween 20 and wells were incubated with alkaline phosphatase-conjugated anti-human Fc (Southern Biotech; P7998) followed by 2 hour incubation. Following incubation, the wells were washed and p-nitrophenyl phosphate substrate solution (Sigma; P7998) was solution was added. Absorbance at 405 nm was measured after approximately 45 min; ELISA performed in triplicate.

Western blot of mAbs: Antibodies were run under reducing and denaturing conditions by SDS-PAGE on a gradient gel with Tris-Glycine buffer. The gel was transferred to a 0.45 μm nitrocellulose membrane (Bio-Rad) using semi-dry transfer. The membrane was blocked in 5% BSA in TBST for 2 hours at room temperature, before probing with a 1:10,000 dilution of biotinylated Aleuria Aurantia Lectin or AAL (Vector Labs; B-1395) in 5% BSA/TBST for 1 hour at room temperature. After 4-6 washes with TBST, the membrane was incubated with a 1: 2500 dilution of streptavidin-HRP (Southern Biotech; 7100-05) in 5% BSA/TBST for 1 hour at room temperature. After 4-6 washes with TBST the membrane was treated with chemiluminescent substrate Western Lightning ECL Pro (Perkin Elmer; NEL120001EA) according to manufacturer’s instructions. The membrane was then imaged using the Amersham Imager 600 (GE Life Sciences) with auto exposure under chemiluminescent detection settings. Post-imaging, the membrane was washed extensively with TBST before treating with Restore™ Western Blot Stripping Buffer (ThermoFisher; 21059) for 15 min at room temperature. To analyze protein loading, the membrane was re-blocked with 5% BSA in TBST for 2 hours at room temperature before probing with 1:5000 dilution of anti-human IgG-HRP (Southern Biotech) in 5% BSA/TBST for 1 hour at room temperature. The membrane was then treated with chemiluminescent substrate, and imaged as described above.

QUANTIFICATION AND STATISTICAL ANALYSIS

All in vitro experiments were performed using three different biological replicates at least three independent times. Normality of Fc glycan distribution was confirmed by Kolmogorov-Smirnov test. Statistical analysis was performed with an unpaired t test. All the analyses were performed using the GraphPad Prism 9 software (Graphpad Software, San Diego, California, USA).